Gene therapies offer a completely new way of treating a range of serious diseases. But before we can realize their full potential, a number of complex regulatory and reimbursement issues must be addressed. IGT is committed to working with stakeholders across the healthcare system to advance policies that will help more patients benefit from gene therapies.
Our new Policy Brief series outlines the four key priorities for the field and articulates solutions that will help remove existing barriers. The series includes:
Along with our new Resources page, which provide background on gene therapies from our Advisory Council members, these tools are designed to help support an environment where gene therapies can flourish.